Related Experiment Videos
Extragonadal abdominal germ cell cancers
J L Gonzalez-Vela1, M A Villalona-Calero, J L Torkelson
1Department of Medicine, University Hospital, Minneapolis, Minnesota.
American Journal of Clinical Oncology
|August 1, 1992
Summary
Treatment with cisplatin-based chemotherapy and surgery offers a 45% long-term survival rate for abdominal germ cell tumors. However, outcomes remain poorer than for testicular germ cell tumors.
Area of Science:
- Oncology
- Pediatric Oncology
- Genitourinary Oncology
Background:
- Abdominal germ cell tumors (GCTs) are rare, particularly in patients with normal physical examination findings of the testes.
- Understanding treatment outcomes is crucial for optimizing patient management.
Purpose of the Study:
- To review the clinical outcomes of patients with abdominal germ cell tumors treated with cisplatin-based chemotherapy.
Main Methods:
- Retrospective chart review of eleven patients diagnosed with abdominal GCTs.
- Analysis of treatment regimens including cisplatin-based chemotherapy and surgical debulking.
- Evaluation of response rates, relapse patterns, and long-term survival.
Main Results:
- Seven out of eleven patients (63%) achieved a complete clinical response.
- Five patients (45%) are long-term disease-free survivors (4-10 years post-diagnosis).
- Patients failing to achieve complete response or relapsing after response died of progressive disease.
Conclusions:
- Cisplatin-based chemotherapy and surgery can lead to long-term survival in a significant proportion of patients with abdominal GCTs.
- Abdominal GCTs have a less favorable prognosis compared to testicular GCTs.
- Outcomes are comparable to mediastinal GCTs.